Ixazomib

From WikiMD.org
Jump to navigation Jump to search

Ixazomib (pronunciation: ik-sa-zo-mib) is an antineoplastic agent used in the treatment of multiple myeloma. It is a proteasome inhibitor that works by blocking the action of proteasomes, thereby preventing the growth of cancer cells.

Etymology

The term "Ixazomib" is derived from the systematic IUPAC name for the compound, which is "N-[(1R)-1-[[(2,5-dichlorobenzoyl)amino]acetyl]-2,3-dihydro-1H-indol-6-yl]-3-(1-pyrrolidinyl)-1-[(1S)-1,2,3,4-tetrahydroisoquinolin-1-yl]-1,3-dihydro-2H-benzimidazol-2-one". The name "Ixazomib" was approved by the World Health Organization (WHO) in 2013.

Related Terms

See Also

References

  • Ixazomib: a review in relapsed and/or refractory multiple myeloma. Drugs. 2017;77(16):1763-1773.
  • Ixazomib, an investigational oral proteasome inhibitor, in patients with relapsed or refractory lymphoma: an overview of preclinical and phase 1 study results. Br J Haematol. 2014;167(4):461-469.

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski